For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Aptinyx Inc. (APTX) one of those stocks right now? Let’s take a closer look at the stock’s year-to-date performance to find out.
Aptinyx Inc. is a member of our Medical group, which includes 1159 different companies and currently sits at #12 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aptinyx Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for APTX’s full-year earnings has moved 6.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that APTX has returned about 15.7% since the start of the calendar year. In comparison, Medical companies have returned an average of -5.1%. This means that Aptinyx Inc. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Doximity (DOCS). The stock is up 4.5% year-to-date.
In Doximity’s case, the consensus EPS estimate for the current year increased 39.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Aptinyx Inc. belongs to the Medical – Biomedical and Genetics industry, a group that includes 539 individual companies and currently sits at #158 in the Zacks Industry Rank. On average, stocks in this group have lost 12.6% this year, meaning that APTX is performing better in terms of year-to-date returns.
On the other hand, Doximity belongs to the Medical Services industry. This 61-stock industry is currently ranked #192. The industry has moved -17.3% year to date.
Investors with an interest in Medical stocks should continue to track Aptinyx Inc. and Doximity. These stocks will be looking to continue their solid performance.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.
See these 7 breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report